Navigation Links
Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
Date:9/24/2008

REINACH, Switzerland, September 24 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced the completion of enrolment in the Phase II 'intravenous-to-oral' switch trial with oral iclaprim in patients with complicated Skin and Skin Structure Infections (cSSSI).

The trial was designed as a multi-centre, double-blind comparative study. Patients suffering from cSSSI received intravenous (IV) vancomycin for the first two days of treatment and were then randomised to either continue to receive IV vancomycin or to be switched to oral iclaprim for eight additional days. A total of 60 patients have been randomised for this study.

The key objective of the study is to assess the clinical efficacy of an oral capsule formulation of iclaprim as step-down therapy in comparison with IV vancomycin in the treatment of cSSSI. The primary endpoint is the clinical cure rate at the Test-of-Cure (TOC) visit. Secondary objectives include bacteriological outcome as well as safety and tolerability.

Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "The speed of enrolment in this Phase II trial surpassed our expectations. It again shows that an 'intravenous-to-oral' step-down therapy serves a medical need and could add significant value to intravenous iclaprim. Marketing applications for intravenous iclaprim have been filed in the U.S.A., the European Union and Canada. We will release the top-line data of this Phase II switch study in the coming months and subsequently determine the path ahead."

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company headquartered in Reinach, Switzerland with operations in Switzerland and the USA. It focuses on the discovery, development and commercialisation of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product can
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Arpida Invited to Present Data on Iclaprim at Scientific Conference
2. Arpida Provides Further Comments on the Pivotal Phase III Trials
3. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
10. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
11. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- Lakeland Industries, Inc. (NASDAQ: LAKE ), a ... and to first responders on the federal, state and ... fiscal 2013 fourth quarter and year ended January 31, ... close and will conduct a conference call on the ... http://photos.prnewswire.com/prnh/20120611/NY21959LOGO ) The call will ...
(Date:5/17/2013)... May 17, 2013   Shareholder rights attorneys  at ... Pharmaceutical, Inc. (NASDAQGS: AVEO) securities has filed a complaint ... Massachusetts .  The complaint alleges that ... Exchange Act of 1934 (the "Exchange Act") between January ... (Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO ) ...
(Date:5/17/2013)... May 17, 2013 Research ... and outcomes research also   to   be presented ... SHPG ), the global specialty biopharmaceutical company, announces ... presentations at the American Psychiatric Association (APA) 166th Annual ... 18-22. The data being presented represent Shire,s ongoing commitment ...
Breaking Medicine Technology:Lakeland Industries to Report Fiscal Fourth Quarter and Year End Financial Results and Conduct Conference Call 2Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 4Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 5Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 6Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 7Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 8Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 9Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 10
... ANF Group, Inc ., a South Florida based ... 170,000-square-foot Joe DiMaggio Children,s Hospital – the first free ... (Photo: http://photos.prnewswire.com/prnh/20110614/FL18288 ) The hospital,s ... designed to earn Gold Leadership in Energy and Environment ...
... June 14, 2011 CVS/pharmacy provides ... at more than 7,200 convenient locations nationwide. Shoppers have come ... larger-than-ever selection of gifts, goods and everyday needs. From popular ... the hottest gear and thoughtful keepsakes perfect for every dad, ...
Cached Medicine Technology:ANF Group, Inc. Completes New Joe DiMaggio Children's Hospital 2Find the Best in Gadgets, Grilling and Grooming in Just One Stop This Father's Day at CVS/pharmacy 2Find the Best in Gadgets, Grilling and Grooming in Just One Stop This Father's Day at CVS/pharmacy 3
(Date:5/20/2013)... when the spotlight is focused on obesity more than ever, ... associated with weight or certain adverse health risks. According to ... of Nutrition Journal , adults who consume candy at ... overweight nor have greater risk factors for cardiovascular disease (CVD) ... frequent candy eaters (less than 3 times per month).1 ...
(Date:5/20/2013)... Brenda Goodman HealthDay Reporter , , SATURDAY, May ... doctors a better view during colonoscopies may help them ... study shows. Colonoscopies are the recommended screening tests ... killer of men and women in the United States. ... flexible tube with a camera mounted on the end ...
(Date:5/20/2013)... HealthDay Reporter , , SUNDAY, May 19 (HealthDay News) -- ... sleep by endlessly and subconsciously waking them up, becomes ... study raises the possibility that it may somehow cause ... Don,t worry just yet if you have sleep ... there may be no connection between the two conditions. ...
(Date:5/20/2013)... News) -- If you,ve got bunions, chances are others ... with a new study finding the condition is often ... the May issue of Arthritis Care & Research ... inherit conditions such as bunions or other toe deformities. ... heritability of common foot disorders in older adults," Dr. ...
(Date:5/20/2013)... 20, 2013) Research presented at Digestive Disease Week ... with diarrhea (IBS-D) and hepatitis C. , An ... IBS-D. In the phase II study, researchers found that ... 50 percent of the individuals treated. , "While ... IBS with constipation, we haven,t seen the same in ...
Breaking Medicine News(10 mins):Health News:New study suggests candy consumption frequency not linked to obesity or heart disease 2Health News:New study suggests candy consumption frequency not linked to obesity or heart disease 3Health News:New Device May Show Doctors More of the Colon 2Health News:New Device May Show Doctors More of the Colon 3Health News:Sleep Apnea in Seniors Tied to Alzheimer's in Study 2Health News:Sleep Apnea in Seniors Tied to Alzheimer's in Study 3Health News:Many Can Blame Family for Their Bunions 2Health News:Pharmaceutical advances offer new options for health outcomes 2
... Identifying those at risk for diabetes is important because lifestyle ... the disease. Currently an oral glucose tolerance test is used ... costly and inconvenient. A new study finds a cluster of ... type 2 diabetes independently of other risk factors. ...
... the births of their first two children are more likely to ... have the same partner.// These babies are ... The results are the same even when researchers take into account ... decades of birth. ,Researchers speculate that women who ...
... Commonwealth's restaurants, taverns, and nightclubs, and voted to lift ... House and Senate concluded the year's business with a ... approved a sales tax "holiday" designed to spur shoppers ... economy, and approved $102 million in extra spending for ...
... new study shows a new drug alternative to warfarin in ... The research shows the drug ximelagatran appears to be as ... for people at high risk of stroke because of its ... include an increased risk of bleeding and a possible interaction ...
... promising therapy option may be more effective in treating the ... disease that causes persistent redness on the nose and cheeks. ... to the faces of rosacea sufferers. //The new product contains ... Typically it has a different formula and is used to ...
... is so easily cured that Luvie Owens almost forgot she ... her cause for concern: Women who have had the most ... to also get deadlier cancers such as breast, lung and ... is 7.5 times higher. ,The study didn't include men, ...
Cached Medicine News:Health News:Predictors for Type 2 Diabetes 2Health News:Changing Partners may put Expectant Mothers at Risk 2Health News:Senate assures ban on smoking 2Health News:Senate assures ban on smoking 3Health News:Senate assures ban on smoking 4Health News:People with skin cancer at higher risk for other types , 2
... workmanship are the hallmark of these stereozoom ... mind. The top (incident) circular 9W fluorescent ... while remaining cool to the touch. Binocular ... 10x to 44x zoom magnification or high-power ...
... IR/DIC video camera. Olympus wide array of high-quality ... quality and flexibility you need for an efficient ... real-time image of your specimen that can be ... You can even record movies when these easy-to-operate ...
... is a premium photomicrography system that ... even the most difficult specimens. Designed with ... system provide solution to the complex problem ... automatic exposure control, the system utilizes special ...
... systems for optimum image quality at low ... color digital camera system is specifically designed ... available. State-of-the-art electronics create bright, vibrant images ... dynamic range offered by the Leica cameras ...
Medicine Products: